Biotech Values

[biomaven0]

I'm having trouble figuring out how Ariad plans to fund their operations past mid-year. An AP-24534 deal would be one source of cash, but trying to rush a deal might not be the best way to maximize its value, and with a lot of interested parties involved, one would think the negotiations could take some time.

All the indications to my mind point to a 534 deal in the near future (I'd predict in the next couple of months). $100m-$150m upfront takes care of their cash for the foreseeable future. The outline of any deal (except with NVS) is pretty straightforward. A NVS deal is obviously much more complex because of Tasigna.

Peter